Paper Details

  1. Home
  2. Paper Details

Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma.

Author: BousquetJ, BrownR, DaleP, TurkF

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study determined the incremental cost-effectiveness ratio (ICER) of adding omalizumab to standard therapy using data from a real-life 1-year randomized open-label study (ETOPA) and using Canada as a reference country. The study demonstrated that add-on omalizumab therapy is cost-effective in patients with severe persistent allergic asthma.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The health, economic and societal burden of asthma is considerable, and is greatest in patients with severe asthma, particularly when inadequately controlled. Real-life studies that assess the effectiveness of treatment are of particular interest. METHODS: We determined the incremental ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1398-9995.2006.01310.x

データ提供：米国国立医学図書館（NLM）

Evaluating the Cost-Effectiveness of Omalizumab for Severe Asthma

This research examines the cost-effectiveness of adding omalizumab to standard therapy for patients with severe persistent allergic asthma. Researchers used real-world data to determine the incremental cost-effectiveness ratio (ICER) of omalizumab. The study found that adding omalizumab was cost-effective in patients with severe persistent allergic asthma.

Finding the Right Balance Between Cost and Effectiveness

This study highlights the importance of considering cost-effectiveness when evaluating treatment options for severe asthma. The research demonstrates that omalizumab can be a valuable tool in managing this condition, providing a cost-effective solution to improve patient outcomes.

Managing Asthma and Improving Quality of Life

This study underscores the importance of effective treatment options for severe asthma. The research highlights the potential of omalizumab to improve quality of life for patients with severe allergic asthma while being cost-effective.

Dr.Camel's Conclusion

This research provides valuable insights into the cost-effectiveness of omalizumab for severe asthma. It's like finding a wellspring of relief in the desert, offering a solution that balances effectiveness with affordability. The study underscores the importance of considering all aspects of patient care, from cost to quality of life, when making treatment decisions.

Date :
  1. Date Completed 2007-07-31
  2. Date Revised 2022-03-11
Further Info :

Pubmed ID

17298423

DOI: Digital Object Identifier

10.1111/j.1398-9995.2006.01310.x

Related Literature

Article Analysis
・Effective treatment of asthma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.